Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials. - Wikidata - awgldk - TriplyDB

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

http://www.wikidata.org/entity/Q34145349

about

Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study Activating clinical trials: a process improvement approach

P2860

Q28395071-FB54A07F-1DEF-41BB-81BA-4EAAF4297D04 Q36611986-796572B5-4405-4D93-BF3F-8145A536294B

P2860

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

http://www.wikidata.org/entity/Q34145349

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@ast

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@en

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@nl

type

label

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@ast

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@en

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@nl

prefLabel

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@ast

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@en

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@nl

P1433

Q34145349-3BF207EB-6CA1-4247-8B26-BA81F8B12951

P1476

Q34145349-C32AD5EC-8E38-4A2E-B1BD-C0DF7AE743E7

P2093

Q34145349-1D3E7888-6FB3-491E-AC69-0947FD90D133

Q34145349-4B42D943-53C0-4184-9410-7AAB4742D070

Q34145349-52AC06B3-90DB-434B-BD9F-6484FFBC55C8

Q34145349-581E7D0A-C5E4-4474-B194-FB32158695AB

Q34145349-6A1EB76E-FB66-4D2D-976E-98771AFE6ADA

Q34145349-B945668F-F3BA-45B7-AD6B-BC830F5F55C0

Q34145349-D7058144-AFC3-4084-AFD2-06677D796967

P2860

Q34145349-16AD4E72-8A47-4547-8673-F6791B420AFC

Q34145349-1D3BE6BA-E76F-43EF-9515-D30E876658ED

Q34145349-26032696-F8D2-4284-A367-7A2FEC274563

Q34145349-4A784A12-B421-44BE-86E3-1B71A36E0D9E

Q34145349-5DAC4805-C53C-4852-9864-1B81C9FC81D4

Q34145349-6CDB189B-DF20-4630-B75C-EF38868C0BE8

Q34145349-967E29DB-7112-42F2-B064-2B6246618A4D

Q34145349-969C0904-DD3D-4370-B03E-F7856950F330

Q34145349-9F0F414A-79BE-4AC9-96D0-532CB36288A5

Q34145349-A6FA97C6-6F53-4D39-8990-A915FD7D81E8

P304

Q34145349-45ABDFF6-0A19-4DC9-96B0-C9D16E685C45

P31

Q34145349-405011C3-8CD5-492E-B50B-B390D60553D2

P356

Q34145349-24460E79-288F-4747-B66D-850939F0AFCA

P433

Q34145349-D094E494-D126-41BA-94E5-4DE8F5C1AC79

P478

Q34145349-68AD3379-CB07-4470-BD0D-99F0400952D7

P577

Q34145349-E698FECD-5509-4C85-B735-69BF74D58028

P698

Q34145349-FA8C5BA4-A537-4CB4-AB94-700EE86CF7F5

P932

Q34145349-0AFFA683-D139-4581-B7F4-9BA9C2ABCF47

P356

1740774514540814

P1433

Clinical Trials

P1476

Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

@en

P2093

Dennis Dixon

http://www.w3.org/2001/XMLSchema#string

Jeffrey T Schouten

http://www.w3.org/2001/XMLSchema#string

Joe Marci

http://www.w3.org/2001/XMLSchema#string

Jonathan M Kagan

http://www.w3.org/2001/XMLSchema#string

Marie T Cope

http://www.w3.org/2001/XMLSchema#string

Scott R Rosas

http://www.w3.org/2001/XMLSchema#string

Suresh Varghese

http://www.w3.org/2001/XMLSchema#string

P2860

The NIAID Division of AIDS enterprise information system: integrated decision support for global clinical research programs

What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies

A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.

Phase III clinical trial development: a process of chutes and ladders

Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials

Integrating utilization-focused evaluation with business process modeling for clinical research improvement

Evaluating translational research: a process marker model

The prevalence and economic impact of low-enrolling clinical studies at an academic medical center.

Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.

A virtual national laboratory for reengineering clinical translational science.

P304

553-559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1740774514540814

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24980279

http://www.w3.org/2001/XMLSchema#string

P932

4156886

http://www.w3.org/2001/XMLSchema#string